Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin (RIBAJUSTE)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2012 by Hospices Civils de Lyon.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Hospices Civils de Lyon Identifier:
First received: June 8, 2007
Last updated: January 6, 2012
Last verified: January 2012
The aim of this study is to compare two therapeutical strategies concerning the combination therapy (peginterferon alfa-2a and ribavirin) in naïve patients with chronic hepatitis C of genotype 1. "Reference" strategy corresponding to standards of care recommended by the French consensus conference versus "Test" strategy corresponding to adaptation strategy of ribavirin dose during the first week according to AUC (area under the curve) of ribavirin plasmatic concentration after the first intake (Day 0) of 600 mg

Condition Intervention Phase
Chronic Hepatitis C
Drug: Peg-interferon alpha 2a and ribavin
Drug: ribavirin with adaptation dose
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicentric, Controlled and Randomised Open Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin Using Pharmacologic Measures of Ribavirin Exposition During Combination Peginterferon Alfa-2 and Ribavirin Treatment in Naive Patients With Chronic Hepatitis C of Genotype 1 on a First Combination Therapy

Resource links provided by NLM:

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • Inter-group comparison of sustained virological response rates as defined by the proportion of subjects with a negative PCR HCV-RNA test at Week 72 [ Time Frame: 72 weeks ]

Secondary Outcome Measures:
  • Efficacy endpoints [ Time Frame: 72 weeks ]
    To compare the virological response rate between the two groups: Rapid Virological Response (RVR) at W4, Early Virological Response (EVR) at W12, Virological Response at W24, and End-Of-Treatment response (EOT) at W48 ; To determine the relapse rate (between W48 and W72) and to determine the proportion of patients reaching the target trough ribavirin concentration of 2 mg/L at W4 or W8 after ribavirin dose adjustment in the first 7 days of treatment.

  • safety endpoints [ Time Frame: 72 weeks ]
    To investigate the clinical and biological tolerability in patients with dose-adjusted ribavirin compared to those with standard ribavirin doses, the proportion of patients needing EPO co-prescription due to secondary anemia in each group, to estimate the rate of treatment discontinuation due to serious or other relevant adverse events in each group and to determine the proportion of subjects reaching ribavirin trough plasma concentrations considered as "toxic" (> 3.5 mg/L) at W4 and W8, in each arm.

  • Economic endpoints [ Time Frame: 72 weeks ]
    Comparaison of the "test" and "standard" strategies by a medico-economic analysis

Estimated Enrollment: 236
Study Start Date: April 2006
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: standard dose
the "reference" strategy : Peg-interferon alpha 2a (180 µg/week) and ribavine (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg)
Drug: Peg-interferon alpha 2a and ribavin

Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg).

Duration of treatment : 48 weeks Duration of study for patients : 72 weeks

Experimental: adjusted dose
individual dose adjustment of ribavirin dose at D7, based on ribavirin abbreviated AUC-0-4H , estimated itself by two independent methods: multiple linear regression and bayesien estimation based on three ribavirin concentration measurements obtained at 0.5H, 1H, 2H after the first intake of 600 mg at D0.
Drug: ribavirin with adaptation dose

Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.

The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 65 years >Age >= 18 years
  • Chronic hepatitis C documented by PCR performed within 3 months and at liver biopsy within 18 months or with serum markers of fibrosis performed within 3 months before inclusion or FibroScan performed
  • Naive patients for who the physician decided to initiate a combination treatment of chronic hepatitis C with pegylated interferon alfa-2a plus ribavirine
  • Genotype VHC-1
  • Compensated liver disease (Child-Pugh <=6)
  • Negative HBsAg test and HIV-RNA test
  • Negative pregnancy test at baseline in women in age of procreation and efficient contraception all along the treatment period, and up to 7 months after discontinuation for women and men
  • Signed consent form
  • Patient with a social cover

Exclusion Criteria:

  • Non HCV liver disease
  • Non-1 HCV genotype
  • Organ transplant whatever the organ
  • Clinical or radiological evidence of liver carcinoma
  • Severe psychiatric disorder
  • Non compensated thyroid dysfunction
  • Woman pregnant or breast-feeding
  • Recent history of epilepsy (less than 6 months)
  • Absolute contraindications to one of the drug of combination therapy
  • Biological abnormalities at pre-treatment check-up, such as:

Neutropenia (<1500/mm³); Haemoglobinemia (<13 g/dL for men et <12 g/dL for women); Thrombopenia (<90 000/mm³);

  • Kidney failure (creatinine clearance>70 ml/min)
  • Hypersensitivity to epoetin or one of its excipients
  • Treatment by epoetin within 2 months prior inclusion
  • Chronic cardiac failure (grade III or IV - NYHA classification)
  • High blood pressure unwell-controlled (SBP > 180 mmHg during inclusion in spite of hypertension treatment)
  • Previous history or risk of venous thrombosis
  • Major surgery within the previous 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00485342

Contact: Marianne Maynard, MD 33 4 72 41 30 88
Contact: Véronique LOUSTAUD-RATTI, MD 33 5 55 05 66 84

Marianne Maynard Recruiting
Lyon, France, 69002
Contact: Marianne Maynard, MD    33 4 72 41 30 88   
Principal Investigator: Christian Trépo, MD         
Sponsors and Collaborators
Hospices Civils de Lyon
Principal Investigator: Christian Trépo, MD Hospices Civils de Lyon
  More Information

Responsible Party: Hospices Civils de Lyon Identifier: NCT00485342     History of Changes
Other Study ID Numbers: 2005-400
Study First Received: June 8, 2007
Last Updated: January 6, 2012

Keywords provided by Hospices Civils de Lyon:
Chronic hepatitis C,Genotype1,Naïf,bitherapy,Ribavirin adaptation,ribavirin AUC

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs processed this record on May 24, 2017